Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2626
    -0.0012 (-0.10%)
     
  • USD/JPY

    151.4390
    +0.1930 (+0.13%)
     
  • Bitcoin USD

    70,730.24
    +1,178.06 (+1.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

BridgeBio Pharma's Candidate For Muscle-Wasting Disorder Wins Fast Track Tag In US

  • The FDA has granted Fast Track Designation to BridgeBio Pharma Inc's (NASDAQ: BBIO) BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i).

  • This is the fifth Fast Track designation for an investigational therapy that BridgeBio has received this year.

  • Clinical trials to verify the safety and efficacy of BBP-418 are ongoing.

  • BBP-418 has received Orphan Drug Designation for the treatment of LGMD2i from the FDA and LGMD from the European Medicines Agency.

  • LGMD2i is a monogenic autosomal recessive disease caused by partial loss of function mutations in the FKRP gene. These FKRP mutations impair glycosylation of α-DG, a protein associated with stabilizing muscle cells.

  • Related Link: FDA Approves BridgeBio Pharma's FGFR2 Inhibitor for Bile Duct Cancer.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: BBIO shares are up 2.61% at $50.00 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement